Skip to main content

Milestone 5.B

Initiate phase II (proof of concept) drug trials for agents against 3-6 currently known therapeutic targets. Of these at least 2 will be for targets involved in at-risk asymptomatic individuals (e.g. FAD or ApoE4 carriers, Down syndrome, amyloid positive, type II diabetes etc.)  These trials will be designed to provide or confirm proof of mechanism and/or evidence of target engagement for the therapeutic agent being tested. 

Success Criteria

Completion of 3-6 phase II drug trials for agents against currently known targets, providing conclusive evidence of therapeutic mechanism/target engagement.

Time Required

2015 to 2018

Research Implementation Area

Drug Development - Existing Targets

CADRO Category

C. Translational Research and Clinical Intervention

Activities, Funding Initiatives, and Resources

NIH Accelerating Medicines Partnership-AD Biomarkers Consortium
NIH ​PAR-16-365: Pilot Clinical Trials for the Spectrum of Alzheimer's Disease …
PAR-14-089: Alzheimer’s Disease Pilot Clinical Trials (R01)
NIH RFA-AG-13-015: Alzheimer’s Disease Prevention Trials (R01)
NIH RFA-AG-13-001: Alzheimer’s Disease Cooperative Study (U19)

Funded Research Projects

IADRP – Category C. Translational Research and Clinical Interventions - 5. Earl…
NIH ​PAR-16-365: Pilot Clinical Trials for the Spectrum of Alzheimer's Disease …
PAR-14-089: Alzheimer’s Disease Pilot Clinical Trials (R01) – Research Projects
NIH RFA-AG-13-015: Alzheimer’s Disease Prevention Trials (R01) – Research Proje…
NIH RFA-AG-13-001: Alzheimer’s Disease Cooperative Study (U19) – Research Proje…